



From Bench to Bedside: Advances in Non-small Cell Lung Cancer in the Era of Precision Oncology

Guest Editor:

Dr. Iyare Izevbaye

Department of Patholog &
Laboratory Medicine, Emory
University, Atlanta, GA, USA

Deadline for manuscript
submissions:

30 September 2024

Message from the Guest Editor

Non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide. Recent progress in the understanding of molecular mechanisms of NSCLC initiation and progression has led to the identification of novel biomarkers for diagnosis and therapy. A better understanding of the interplay between intrinsic cancer cell mechanisms and the extrinsic tumor microenvironment is a gateway towards innovation and biomarker development in immune checkpoint inhibition (ICI) therapy. Advances in next-generation sequencing have made comprehensive genomic profiling (CGP) a mainstay for therapy selection. Techniques such as liquid biopsy in the management of NSCLC enable the noninvasive acquisition of diagnostic and surveillance samples, the use of diagnostic predictive modeling has further advanced the goals of precision medicine.

This Special Issue on NSCLC aims to highlight recent advances from bench-to-bedside research in NSCLC in the era of genomics and precision medicine. We seek original basic and translational studies and review articles in NSCLC pathogenesis, biomarker discovery, and development and laboratory genomic medicine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI